Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar 16;107(11):5112-7.
doi: 10.1073/pnas.0915141107. Epub 2010 Feb 26.

From combinatorial peptide selection to drug prototype (I): targeting the vascular endothelial growth factor receptor pathway

Ricardo J Giordano  1 , Marina Cardó-Vila, Ahmad Salameh, Cristiane D Anobom, Benjamin D Zeitlin, David H Hawke, Ana P Valente, Fábio C L Almeida, Jacques E Nör, Richard L Sidman, Renata Pasqualini, Wadih Arap
Affiliations

From combinatorial peptide selection to drug prototype (I): targeting the vascular endothelial growth factor receptor pathway

Ricardo J Giordano et al. Proc Natl Acad Sci U S A. .

Abstract

Inhibition of blood vessel formation is a viable therapeutic approach in angiogenesis-dependent diseases. We previously used a combinatorial screening on vascular endothelial growth factor (VEGF)-activated endothelial cells to select the sequence CPQPRPLC and showed that the motif Arg-Pro-Leu targets VEGF receptor-1 and neuropilin-1. Here, we evaluated and validated (D)(LPR), a derivative molecule with strong antiangiogenesis attributes. This prototype drug markedly inhibits neovascularization in three mouse models: Matrigel-based assay, functional human/murine blood vessel formation, and retinopathy of prematurity. In addition to its systemic activity, (D)(LPR) also inhibits retinal angiogenesis when administered in an eye-drop formulation. Finally, in preliminary studies, we have showed targeted drug activity in an experimental tumor-bearing mouse model. These results show that drugs targeting extracellular domains of VEGF receptors are active, affect signal transduction, and have potential for clinical application. On a larger context, this study illustrates the power of ligand-directed selection plus retro-inversion for rapid drug discovery and development.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Drug design and protease degradation-resistance assay. (A) Schematic representation of Arg-Pro-Leu (RPL) retro-inversion. (B and C) Mass-spectroscopy analysis (MALDI-TOF) of RPL and D(LPR) pre- and postincubation with pancreatic enzymes. Peaks corresponding to the intact peptides and enzymatic degradation products are color-coded [red, RPL; blue, D(LPR)] and indicated by arrows.
Fig. 2.
Fig. 2.
The tripeptide RPL and the drug D(LPR) target VEGFR-1 and NRP-1. (A) In a phage-competition assay, increasing concentrations of RPL (black circles) or D(LPR) (open squares) inhibit binding of CPQPRPLC-displaying phage to the immobilized receptors VEGFR-1 or NRP-1. (B) Chemical-shift changes induced on the D(LPR) peptidomimetic resonances by its binding to VEGFR-1 or NRP-1 at 25 °C are shown. 2D TOCSY spectra of D(LPR) alone (black color) or in the presence of the individual receptors (red color) are shown. Different regions of the spectra of D(LPR) are shown to indicate chemical-shift changes in individual D(LPR) residues.
Fig. 3.
Fig. 3.
Inhibition of neovascularization in vivo by D(LPR) treatment. (A) Representative pictures of Matrigel plugs containing 500 μg/mL of D(LPR) or control after 7 days of implantation (Lower). Matrigel plugs were excised, and angiogenesis was quantified by measurement of the hemoglobin content within the matrix. The bar graph shows representative mice from the experiment (Upper). (B) Immunostaining with anti-human factor VIII antibody of scaffolds containing human microvascular endothelial cells (HDMEC) implanted into SCID mice that received 25 mg/kg i.p. daily of D(LPR) or control. (C) Number of human factor VIII-positive blood vessels at 200× magnification. *Student’s t test (P < 0.01).
Fig. 4.
Fig. 4.
Systemic and topical treatment with D(LPR) inhibits retinal angiogenesis in a mouse retinopathy-of-prematurity model. Retinal neovascularization was induced in C57BL/6 neonatal mice by exposure to 75% oxygen (P7–P12) followed by daily i.p. administration of D(LPR) or control (20 mg/kg per day). (A) H&E-stained retinal sections (P19) showed new blood vessels at the retinal inner surface (arrows) in control animals (Top and Center). There was marked reduction in D(LPR)-treated mice (Bottom). (B) P19 quantification of neovascular nuclei protruding into the vitreous space. Serial sections (n > 5) of eyes (n > 10) were quantified in each group. Treatment with D(LPR) yielded a significant reduction in nuclei relative to vehicle or control. (C) In systemic (i.p.) delivery, the magnitude of D(LPR)-induced neovascularization inhibition was similar to that observed by treatment with the monoclonal antibody bevacizumab. (D) Topical delivery of D(LPR) in an eye-drop formulation (200 μg e.d. three times daily) also induced a significant reduction in abnormal retinal angiogenesis. Shown is mean ± SEM in each experiment.*, Student’s t test (P < 0.05).
Fig. 5.
Fig. 5.
CPQPRPLC-targeted phage homed to tumors, and D(LPR) treatment reduced tumor growth. (A) Tumor-bearing mice received 1010 transducing units (TU) of either CPQPRPLC phage or insertless phage (negative control). After 24 h of circulation, phage homing to tissues was evaluated by counting the relative TU. The brain served as a negative control organ. (B) Tumor-bearing mice (n = 7 per cohort) were treated with vehicle alone, D(LPR), or control peptide (50 mg/kg/day for 5 days). Two independent experiments were performed with similar results. A representative experiment is shown. *Student’s t test (P = 0.02).
Fig. 6.
Fig. 6.
Effect of D(LPR) on VEGFR-1–meditated endothelial cell proliferation and signaling. (A) Dose-dependent effect of D(LPR) on PlGF-induced HUVEC proliferation. Results are presented as values relative to BSA. (B) Immunoblot analysis of phosphorylated and total forms of VEGFR-1, ERK, and Akt. P1GF was used at 100 ng/mL, and D(LPR) or control was used at 10 μg/mL.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med. 1971;285:1182–1186. - PubMed
    1. Folkman J. Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6:273–286. - PubMed
    1. Arden GB, Sidman RL, Arap W, Schlingemann RO. Spare the rod and spoil the eye. Br J Ophthalmol. 2005;89:764–769. - PMC - PubMed
    1. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438:932–936. - PubMed
    1. Loges S, Roncal C, Carmeliet P. Development of targeted angiogenic medicine. J Thromb Haemost. 2009;7:21–33. - PubMed

Publication types

MeSH terms

LinkOut - more resources